A research group led by Assistant Professor Eiichi Kodama of Division of Emerging Infectious Diseases, Tohoku University Hospital, along with Yamasa Corporation (Choshi, Chiba Prefecture), Kumamoto University, Kyoto University, and Yokohama College of Pharmacy in collaboration, has entered into an exclusive licensing agreement with Merck & Co., Inc. (Whitehouse Station, NJ) for the development of a novel therapeutic drug against infections of highly resistant human immunodeficiency virus (HIV) with plans for full scale clinical development.

More information (Japanese)

[Contact]

Assistant Professor Eiichi Kodama

Division of Comprehensive Infections

Tohoku University Hospital

TEL: +81-22-717-7199

E-mail: kodama515*med.tohoku.ac.jp (Replace * with @)

[Public Relations]

Associate professor Fuji Nagami

Public Relations Office of Tohoku University Graduate School of Medicine

Tel: +81-22-717-7908 Fax: +81-22-717-8187

E-mail: f-nagami*med.tohoku.ac.jp (Replace * with @)